| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Research Abstract |
ATL is one of the most aggressive hematologic malignancies caused by human T-lymphotropic virus type 1 (HTLV-1) infection. The prognosis of ATL is extremely poor; however, effective strategies for diagnosis and treatment have not been established. 2-step statistical analysis for 14,064 peptides detected through focused proteomic profiling of the HTLV-1 enriched CD4^+CD25^+CCR4^+ T-cell subpopulation on 29 clinical cases were performed. 91 peptide determinants that statistically classified 4 clinical groups with an accuracy rate of 92.2% by cross-validation test were extracted, resulting in the identification of 17 classifier proteins which were potential diagnostic biomarkers and an attractive resource of therapeutic targets for ATL.
|
